Insider Profile
Tropeano, Lauren Anne
1
Companies Filed At
2
Open-Market Buys (2yr)
$39K
Buy Value (2yr, open-market)
Jun 11, 2026
Most Recent Trade
2
Credibility
Score
0%
Hit Rate
-10.5%
Avg 90d Return
-10.5%
Median 90d Return
4
Evaluated Trades
-10.5%
Best Trade
-10.5%
Worst Trade
Hit rate and returns are based on 4 open-market buys with evaluable 90-day outcomes. Score reflects historical conviction, not a guarantee of future performance. Limited signal — either below-average timing or insufficient trade history.
Cross-Company Track Record
THIN HISTORY
—
Hit Rate · 90d
-10.4%
Median Alpha · 90d
1
Closed Buys Evaluated
0%
Beat XIU
All-insider base rate: 59% hit rate  · +1.3% mean alpha (n=11504)
size concentrated
Entry: closing price on SEDI filing date (point-in-time). Exit: 90 calendar days later. Alpha vs XIU.TO (iShares TSX 60). Closed trades only. Not investment advice.
Research 1 closed buys with individual return outcomes available on the Research plan.
Date Company Role Nature Dir. Shares Price Value Score
Jun 11, 2026 $DCBO
Docebo
— Exercise Sell 739 — — 43
Jun 11, 2026 $DCBO
Docebo
— Open Market Buy 367 $17.97 $7K 43
Jun 11, 2026 $DCBO
Docebo
— Exercise Buy 739 — — 43
Mar 31, 2026 $DCBO
Docebo
— Comp. Grant Buy 35,117 — — 43
Mar 11, 2026 $DCBO
Docebo
— Exercise Sell 2,959 — — 43
Mar 11, 2026 $DCBO
Docebo
— Exercise Buy 2,959 — — 43
Mar 11, 2026 $DCBO
Docebo
— Open Market Buy 1,468 $22.32 $33K 43
Mar 11, 2025 $DCBO
Docebo
— Comp. Grant Buy 26,157 — — 43
Mar 11, 2025 $DCBO
Docebo
— Comp. Grant Buy 26,157 — — 43
Mar 11, 2025 $DCBO
Docebo
— Comp. Grant Buy 26,157 — — 43
Mar 11, 2025 $DCBO
Docebo
— Comp. Grant Buy 11,835 — — 43
Jan 07, 2025 $DCBO
Docebo
— Other Sell — — — 43
Jan 07, 2025 $DCBO
Docebo
— Other Sell — — — 43
Muted rows are plan purchases, compensation grants, or DRIP — not open-market. Confluence Scores reflect the company's current score, not the score at time of trade.
Form55 provides data and analysis for informational purposes only. Nothing on this site constitutes investment advice or a recommendation to buy or sell any security. Past performance is not indicative of future results.